Radar Therapeutics has raised USD 13.4 million in an oversubscribed seed funding round led by NfX Bio, with participation from Eli Lilly and Company, Biovision Ventures, and KdT Ventures, among others.
The raised funds are expected to be channeled toward advancing Radar’s internal programs, including its programmable mRNA-based therapeutics, team expansion, and strategic partnering initiatives.
Radar Therapeutics is a biotechnology company specializing in developing advanced programmable genetic and mRNA-based therapeutics that use RNA sensors. Its RADAR platform enables precision therapeutics through controlled reading of the mRNA in targeted cells, protecting non-target cells from toxic side effects.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.